The mechanism of action of Pudilan Xiaoyan oral liquid against LPS-induced acute respiratory infection in mice based on biological network analysis and metabolomics
10.16438/j.0513-4870.2020-1585
- VernacularTitle:基于生物网络和代谢组学研究蒲地蓝消炎口服液抗LPS诱导小鼠急性呼吸道感染的作用机制
- Author:
Gang TIAN
1
;
Yuan-zhuo HU
2
;
Chao LI
1
;
Yuan-yuan ZHAI
2
;
Bei-hua BAO
2
;
Wei-feng YAO
2
;
Li ZHANG
2
;
An-wei DING
2
Author Information
1. Jumpcan Pharmaceutical Co., Ltd., Taizhou 225411, China
2. School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China
- Publication Type:Research Article
- Keywords:
Pudilan Xiaoyan oral liquid;
network pharmacology;
metabolomics;
LPS;
acute respiratory infection
- From:
Acta Pharmaceutica Sinica
2021;56(3):816-822
- CountryChina
- Language:Chinese
-
Abstract:
This study integrates metabolomics and network pharmacology techniques to systematically analyze the possible mechanism of Pudilan Xiaoyan oral liquid (PDL) in the treatment of acute respiratory infections. GC-MS metabolomics analysis found 8 endogenous metabolites, 3-phosphoglycerate, α-aminoadipate, D-ribulose-5-phosphate, β-mannosylglyceric acid, D-fructose, urea, D-maltose and ornithine in the serum of mice with acute respiratory infection induced by LPS; these substances can be used as biomarkers for PDL use in the treatment of acute respiratory infections. Biological network studies revealed 10 potential targets for intervention by PDL in the glycolysis and pentose phosphate pathways, including GPI, G6PD, H6PD, PFKM, TALDO1, TKT, GAPDH, HK1, PKLR and TPI1. All animal experiments were carried out with approval of the Animal Ethics Committee of Nanjing University of Chinese Medicine. Our findings indicate that the strategy of combining metabolomics and network analysis can provide information on the possible mechanism of PDL in acute respiratory infections, and reveal that PDL may ameliorate the pathological process of acute respiratory infections by regulating disordered metabolic pathways.
